NCCM
LRMR icon

Nine Chapters Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Nine Chapters Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,033
Closed -$170K – 121
2017
Q1 		$170K Buy
+3,033
New +$151K 0.23% 172

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Nine Chapters Capital Management's LRMR Position: Q2 2017 in Review

Nine Chapters Capital Management sold out of Larimar Therapeutics (LRMR) in Q2 2017, closing a stake of 3,033 shares — an estimated $170K sold.

Nine Chapters Capital Management first reported a position in LRMR in Q1 2017 and held it in 1 quarter. The position peaked at $170K in Q1 2017. 69 funds tracked by Wall St. Rank hold LRMR as of Q2 2017.

  • Nine Chapters Capital Management reported no remaining Larimar Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Nine Chapters Capital Management sold 3,033 Larimar Therapeutics shares in Q2 2017, an estimated $170K.
  • Nine Chapters Capital Management first reported a position in Larimar Therapeutics in Q1 2017 and held it in 1 quarter.
  • Nine Chapters Capital Management's Larimar Therapeutics position peaked at $170K in Q1 2017.
  • 69 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2017.

Based on Nine Chapters Capital Management's 13F filing for Q2 2017, filed 31 Jul 2017.